FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>LEIDEN JEFFREY M</u>				<u>V</u>	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]							5. Relationship of Reporting (Check all applicable) X Director			Person(s) to Issuer 10% Owner		
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS					3. [3. Date of Earliest Transaction (Month/Day/Year) 02/11/2019							X	Officer (give title Other (specify below) CEO & President			
50 NORTHERN AVENUE (Street) BOSTON MA 02210 (City) (State) (Zip)			4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Indiv Line) X	ridual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person					
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/		Execution Date,		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and			5)	5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
								Code	V	Amount	(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)			(Instr. 4)
Common Stock 02/11/20				19	9		S ⁽¹⁾		14,707	D	\$179.2	28(2)(3)	2	23,916	D		
Common Stock 02/11/201				19	9		S ⁽¹⁾		47,661	D	\$179.9	3(3)(4)	1	76,255	D		
Common Stock 02/11/201				19	9		S ⁽¹⁾		48,651	D	\$180.8	31 ⁽³⁾⁽⁵⁾	1	27,604	D		
Common Stock 02/11/201				19	9		S ⁽¹⁾		412	D	\$181.	8(2)(6)	1	27,192	D		
Common Stock														440	I	401(k)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	vative Conversion Date Execution Date, irity or Exercise (Month/Day/Year) if any			ransaction of ode (Instr. Derivative		e Kilometer (Mo	Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. : and 4)		ivative de urity Se tr. 5) Be Ov Fo Re Tr	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(: (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A) (D)	Dai Exc	te ercisabl	Expiration Date	Title	Number of Shares					

Explanation of Responses:

- 1. Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1.
- $2. Open \ market \ sales \ reported \ on \ this \ line \ occurred \ at \ a \ weighted \ average \ price \ of \ \$179.28 \ (range \ \$178.47 \ to \ \$179.47).$
- 3. Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- $4. \ Open \ market \ sales \ reported \ on this line \ occurred \ at \ a \ weighted \ average \ price \ of \ \$179.93 \ (range \ \$179.48 \ to \ \$180.47).$
- 5. Open market sales reported on this line occurred at a weighted average price of \$180.81 (range \$180.48 to \$181.45).
- $6. \ Open \ market \ sales \ reported \ on \ this \ line \ occurred \ at \ a \ weighted \ average \ price \ of \ \$181.80 \ (range \ \$181.52 \ to \ \$181.81).$

Remarks:

/s/ Omar White, Attorney-in-02/13/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.